These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Adjuvant interferon in the treatment of melanoma. Middleton MR Br J Cancer; 1999 Aug; 80(11):1679-80. PubMed ID: 10468281 [No Abstract] [Full Text] [Related]
3. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?]. Saiag P Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432 [No Abstract] [Full Text] [Related]
8. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma. Johnson DM; Hayat SQ; Burton GV J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440 [No Abstract] [Full Text] [Related]
9. A case of animal-type melanoma (or pigmented epithelioid melanocytoma?): an open prognosis. Vezzoni GM; Martini L; Ricci C Dermatol Surg; 2008 Jan; 34(1):105-9; discussion 110. PubMed ID: 18053035 [No Abstract] [Full Text] [Related]
10. The Sunbelt Melanoma Trial. McMasters KM Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897 [TBL] [Abstract][Full Text] [Related]
12. Meeting report from the Third Global Workshop on Melanoma. Agarwala SS; di Pietro A; Flaherty KT; Garbe C; Grob JJ; Kashani-Sabet M; Kirkwood JM; Leachman S; Messina J; O'Day S; Ribas A; Sondak V Pigment Cell Melanoma Res; 2010 Oct; 23(5):e1-7. PubMed ID: 20718940 [No Abstract] [Full Text] [Related]
13. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. Bajetta E Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604 [No Abstract] [Full Text] [Related]
15. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse. Gale DM; Kiley KE Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250 [TBL] [Abstract][Full Text] [Related]
17. Where are we with adjuvant therapy of stage III and IV melanoma in 2009? Fecher LA; Flaherty KT J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062 [TBL] [Abstract][Full Text] [Related]
18. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534 [No Abstract] [Full Text] [Related]
19. Adjuvant therapy of melanoma. Retsas S Lancet; 1998 Aug; 352(9129):737-8. PubMed ID: 9729017 [No Abstract] [Full Text] [Related]
20. The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. Eggermont AM; Keilholz U; Testori A; Cook M; Lienard D; Ruiter DJ Ann Surg Oncol; 2001 Oct; 8(9 Suppl):38S-40S. PubMed ID: 11599896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]